Page 34 - 83_02

Colorectal cancer: prevention and treatment
20. Giovannucci E. Insulin, Insulin-Like Growth Factors
and Colon Cancer: A Review of the Evidence. J Nutr.
2001;131(11):3109–20.
21. Lee YC; Lee YL, Chiang JP, Lee JC. Differences in
survival between colon and rectal cancer from SEER
data. Los One 2013. 8(11):e78709.
22. Slattery ML, Edwards S, Curtin K, Ma K, Edwards R,
Holubkov R, Schaffer D. Physical activity and
colorectal cancer. Am J Epidemiol. 2003;158(3):214-
24.
23. Mehta M, Shike M. Diet and physical activity in the
prevention of colorectal cancer. J Natl Compr Canc
Netw. 2014;12(12):1721-6.
24. Rosenberg L, Boggs D, Wise LA, Palmer JR, Roltsch
MH, Makambi KH et at. A follow-up study of
physical activity and incidence of colorectal polyps in
African-American women. Cancer Epidemiol
Biomarkers Prev. 2006;15(8):1438-42.
25. Van Blarigan EL, Meyerhardt JA. Role of Physical
Activity and Diet After Colorectal Cancer Diagnosis. J
Clin Oncol. 2015;33(16):1825-34.
26. Wolin KY, Patel AV, Campbell PT, Jacobs
EJ, McCullough ML, Colditz GA et al. Change in
physical activity and colon cancer incidence and
mortality. Cancer Epidemiol Biomarkers
Prev. 2010;19(12):3000-4.
27. Riondino S, Roselli M, Palmirotta R, Della-Morte D,
Ferroni P, Guadagni F. Obesity and colorectal cancer:
role of adipokines in tumor initiation and progression.
World J Gastroenterol. 2014;20(18):5177-90.
28. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y et al.
Obesity and risk of colorectal cancer: a systematic
review of prospective studies. PLoS One.
2013;8(1):e53916.
29. Diergaarde B, Vrieling A, Van Kraats AA, Van
Muijen GN, Kok FJ, Kampman E. Cigarette smoking
and genetic alterations in sporadic colon carcinomas.
Carcinogenesis. 2003;24(3):565-71.
30. Cho E, Smith-Warner SA, Ritz J, Van den Brandt PA,
Colditz GA, Folsom AR et al. Alcohol intake and
colorectal cancer: a pooled analysis of 8 cohort
studies. Ann Intern Med. 2004;140(8):603-13.
31. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti
L, Islami F et al. Alcohol drinking and colorectal
cancer risk: an overall and dose-response meta-
analysis of published studies. Ann 2011;22(9):1958-
72.
32. Kontou N, Psaltopoulou T, Soupos
N, Polychronopoulos E, Xinopoulos D, Linos A et al.
Al Alcohol consumption and colorectal cancer in a
Mediterranean population: a case-control study. Dis
Colon Rectum. 2012 Jun;55(6):703-10.
33. World Health Organization. World Health Statistics
2015. Disponible en:
http://apps.who.int/iris/bitstream/10665/170250/1/978
9240694439_eng.pdf?ua=1&ua=1.
@Real Academia Nacional de Farmacia. Spain
34. López Torres G, Hernández Carmona A. Cribado del
cáncer colorrectal. AMF 2010;6(6):338-45.
35. Dhaliwal A, Vlachostergios PJ, Oikonomou KG,
Moshenyat Y. Fecal DNA testing for colorectal cancer
screening: Molecular targets and perspectives. World
J Gastrointest Oncol. 2015;7(10):178–83.
36. Singh S, Slingh PP, Murad MH, Singh H, Samadder
NJ. Prevalence, Risk Factors and Outcomes of
Interval Colorectal Cancers: A Systematic Review and
Meta-Analysis. Am J Gastroenterol.
2014:109(9);1375-89.
37. Chattree A, Lee T, Guota S, Rutter MD. Management
of colonic polyps and the NHS Bowel Cancer
Screening Programme. Br J Hosp Med (Lond).
2015:76(3):132-7.
38. Cheng Y, Yang H, Chen G, Zhang Z. Moleculary
targeted drugs for metastatic colorectal cancer. Drug
Des Devel Ther. 2013;7: 1315–22.
39. Price TJ, Segelov E, Burge M, Haller DG, Ackland
SP, Tebbutt NC et al. Current opinion on optimal
treatment for colorectal cancer. Expert Rev Anticancer
Ther. 2013;13(5):597-611.
40. Montagnani F, Chiriatti A, Turrisi G, Francini
G, Fiorentini G. A systematic review of FOLFOXIRI
chemotherapy for the first-line treatment of metastatic
colorectal cancer: improved efficacy at the cost of
increased toxicity. Colorectal Dis. 2011;13(8):846-52.
41. Souglakos J, Androulakis N, Syrigos K, Polyzos
A, Ziras N, Athanasiadis A et al. FOLFOXIRI (folinic
acid, 5-fluorouracil, oxaliplatin and irinotecan) vs
FOLFIRI (folinic acid, 5-fluorouracil and irinotecan)
as first-line treatment in metastatic colorectal cancer
(MCC): a multicentre randomised phase III trial from
the Hellenic Oncology Research Group (HORG). Br J
Cancer. 2006;94(6):798-805.
42. Cersosimo RJ. Management of advanced colorectal
cancer, Part 1. Am J Health Syst
Pharm. 2013;70(5):395-406.
43. Cersosimo RJ. Management of advanced colorectal
cancer, Part 2. Am J Health Syst
Pharm. 2013;70(6):491-506.
44. Van der Wilt CL, Pinedo HM, Smid K, Cloos J,
Noordhuis P, Peters GJ. Effect of folinic acid on
fluorouracil activity and expression of thymidylate
synthase. Semin Oncol. 1992;19(3):16-25.
45. Sargent DJ, Marsoni S, Monges G, Thibodeau Sn,
Labianca R, Hamilton SR et al. Defective mismatch
repair as a predictive marker for lack of efficacy of
fluorouracilbased adjuvant therapy in colon cancer. J
Clin Oncol. 2010;28(20), 3219–26.
46. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP,
Colangelo LH, Petrelli NJ et al. Oxaliplatin as
adjuvant therapy for colon cancer: updated results of
NSABP C-07 trial, including survival and subset
analyses. J Clin Oncol. 2011;29(28):3768–74.
47. Haller DG, Tabernero J, Maroun J, de Braud F, Price
T, Van Cutsem E et al. Capecitabine plus oxaliplatin
197